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Abstract
Background: Sex hormones may be associated with a higher incidence of ischemic stroke or stroke-related events.
In observational studies, lower testosterone concentrations are associated with infirmity, vascular disease, and
adverse cardiovascular risk factors. Currently, female sexual hormones are considered neuroprotective agents. The
purpose of this study was to assess the role of sex hormones and the ratio of estradiol/testosterone (E/T) in patients
with acute ischemic stroke (AIS).
Methods: Between January 2011 and December 2016, 146 male patients with AIS and 152 age- and sex-matched
control subjects were included in this study. Sex hormones, including estradiol, progesterone, and testosterone,
were evaluated in the AIS patient and control groups. We analyzed the clinical and physiological levels of sex
hormones and hormone ratios in these patients.
Results: The E/T ratio was significantly elevated among patients in the stroke group compared to those in the
control group (P = 0.001). Categorization of data into tertiles revealed that patients with the highest E/T ratio were
more likely to have AIS [odds ratio (OR) 3.084; 95% Confidence interval (CI): 1.616-5.886; P < 0.001) compared with
those in the first tertile. The E/T ratio was also an independent unfavorable outcome predictor with an adjusted OR
of 1.167 (95% CI: 1.053-1.294; P = 0.003).
Conclusions: These findings support the hypothesis that increased estradiol and reduced testosterone levels are
associated with AIS in men.
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Background
Sex hormones act on the brain via both genomic and
non-genomic receptors [1]. Previous preclinical evidence
had shown that sex hormones play an important neuro-
protective role following acute ischemic stroke (AIS) and
other acute central nervous system conditions such as
spinal cord and traumatic brain injuries [2]. Sex
hormones exert their effects directly on neuronal death
pathways, and indirectly by modulating the immune sys-
tem. The effects of these hormones on stroke outcomes
are dose-dependent and are further associated with the
patient’s age [3]. Age has been linked to the prediction
of cardio-metabolic risk. Sex hormones play multiple
roles in the development of cardiovascular disease [4].
There are similarities and differences in sex hormones
between males and females. Aging has a significant im-
pact on estrogen and androgen levels in both sexes. In
particular, while estrogen levels decrease drastically only
in post-menopausal women, androgen levels gradually
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begin to decrease around 30 years of age in both sexes
[5–7].
Interestingly, both clinical and experimental evidence
suggest that androgen levels drop after ischemic stroke.
This raises the question of whether ischemia-induced re-
duction in androgen levels may be as important as the
steady levels of hormones prior to the insult. Some re-
cent bench studies have revealed conflicting data and in-
dicate that androgens can either prevent or exacerbate
ischemic damage [8].
The classical endogenous and exogenous sex hor-
mones (estrogen, testosterone, and progesterone) have
profound effects on stroke incidence, risk factors, and
various outcomes. Few studies have examined the direct
or indirect effects of sex hormones in the treatment of
ischemic stroke [9–11]. Although the available evidence
supports the hypothesis that sex hormones may be asso-
ciated with the pathophysiology of AIS, it remains to be
determined whether these hormones affect the acute
stage of the condition. The goal of this study was to (1)
determine the physiological levels of the principal sex
hormones in AIS; (2) investigate the relationship be-
tween the possible sex hormone ratio including estra-
diol/testosterone (E/T) ratio, estradiol/free testosterone
(E/free T) ratio, and AIS; and (3) investigate the associ-




The AIS patient group consisted of 146 consecutively
enrolled male patients who had been admitted within 48
hours of the onset of symptoms to our neurology de-
partment from January 2011 to December 2016. The
control group consisted of 152 age-matched neurologic-
ally healthy males without any recent history of stroke
or other thrombotic events. The control participants
were recruited from the outpatient clinic of our hospital
during their scheduled health examinations. This study
was conducted according to the guidelines of the Declar-
ation of Helsinki and approved by the institutional hu-
man research ethical committee (IRB approval no. 2011-
004). Informed consent was obtained from all
participants.
Risk factor assessment
We assessed the vascular risk factors including atrial fib-
rillation, cardiovascular disease (such as coronary heart
disease, heart failure, and peripheral arterial disease),
hypertension (HTN), diabetes mellitus (DM), hyperlipid-
emia, chronic kidney disease (CKD), and current smok-
ing and alcohol drinking habits, in all participants. HTN
was diagnosed when a patient demonstrated systolic
blood pressure (SBP) ≥ 140 mmHg, diastolic blood
pressure (DBP) ≥ 90 mmHg, or was receiving antihyper-
tensive treatment. Diabetes was diagnosed when a pa-
tient had fasting plasma glucose level ≥ 7.0 mmol/L,
hemoglobin A1c (HbA1c) ≥ 6.5 %, or had been receiving
oral hypoglycemic agents or insulin [12]. We also deter-
mined serum levels of total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides (TG), and estimated
glomerular filtration rate (eGFR). Body mass index
(BMI) was determined as the measured weight in kilo-
grams divided by the measured height in meters
squared. Hyperlipidemia was diagnosed as total choles-
terol level > 6.21 mmol/L, LDL cholesterol > 4.14 mmol/
L, or in patients receiving lipid-lowering medication. We
did not include patients with severe hepatic dysfunctions
(alanine aminotransferase or aspartate aminotransferase
levels > 2 times the upper limit of normal value), renal
dysfunction (serum creatinine > 141.4 µmol/L), recent
history of infection, malignancy, previous history of per-
ipheral vascular occlusive disease, autoimmune disease,
or any other neurological disorders.
Assessment of stroke severity and outcomes
All patients with AIS underwent brain magnetic reson-
ance imaging (MRI) and angiographic studies (MR angi-
ography, computerized tomography angiography, or
conventional cerebral angiography). The severity of initial
neurological deficits was assessed using the National Insti-
tutes of Health Stroke Scale (NIHSS). Functional neuro-
logical outcomes were assessed using the modified Rankin
Scale (mRS) at discharge. Unfavorable outcomes were de-
fined as mRS score > 2. Etiological stroke subtypes were
determined according to the Trial of ORG 10,172 in
Acute Stroke Treatment classification system [13].
Data collection and laboratory examinations
All blood samples were obtained prior to treatment
(with an anticoagulant and/or antiplatelet agent). Serum
specimens were centrifuged, frozen within 2 h of collec-
tion, and stored at − 80 ºC until analyzed. The following
concentrations of components were measured using the
methods specified by the manufacturer: glucose, total
cholesterol, HDL cholesterol, LDL cholesterol, TG, cre-
atinine, uric acid, and HbA1c. Plasma sex hormone
levels were also determined at the hospital laboratory
using a biochemical analyzer (COBAS e 411 analyzer,
Roche, Mannheim, Germany). E/T and E/free T ratios
were defined as the ratio of estradiol to total testoster-
one and the ratio of estradiol to free testosterone,
respectively.
Statistical analyses
Statistical analyses were performed using SPSS (version
23.0; IBM SPSS Statistics, Armonk, NY, USA). Student’s
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t-test or the Mann-Whitney U test was used to compare
continuous variables between the patient and control
groups. The Chi-square or Fisher’s exact test was used
to compare categorical variables. Values were expressed
as mean ± standard deviation or number (percentage), as
appropriate. Bivariate correlations between sex hor-
mones and other parameters were compared using Pear-
son’s correlation test. Logistic regression analysis was
used to determine the relationship between risk factors
and AIS. The relation of risk factors with unfavorable
functional outcomes (assessed by “at discharge” mRS
score) was also investigated with the use of logistic re-
gression models. After univariate analyses, odds ratios
(ORs) with 95 % confidence intervals (CIs) were calcu-
lated using multivariate logistic regression. The goodness
of fit of this model was assessed using the Hosmer and
Lemeshow chi-squared statistic. All statistical tests were
two-sided, and P < 0.05 was considered statistically
significant.
Results
Clinical and biochemical baseline demographic charac-
teristics of the study participants are summarized in
Table 1. A total of 146 patients with AIS were matched
to 152 participants without the condition. The levels of
SBP, DBP, total cholesterol, and TG were significantly
higher, while the eGFR was significantly lower in the
AIS group than in the control group. There were no dif-
ferences between the AIS and control groups in BMI,
DM, smoking, alcohol consumption, hyperlipidemia,
HDL cholesterol, LDL cholesterol, and HbA1c. There
were significant differences between the two groups in
the percentage of HTN, cardiovascular disease, atrial fib-
rillation, and CKD. In addition, the characteristics of sex
hormones are also presented in Table 1. There were no
significant differences in the levels of estradiol, total tes-
tosterone, free testosterone, progesterone, and 17-OH
progesterone between the groups (Table 1). However,
the two groups differed significantly in the E/T ratio.
All participants were categorized into tertiles accord-
ing to the E/T ratio. When the baseline demographic
and clinical characteristics of the participants were ex-
amined, there were significant differences between the
tertiles in age, prevalence of AIS, SBP, BMI, DM, and
current smoking and alcohol drinking habits (Table 2).
Participants with the highest tertile E/T ratio were older
and had higher SBP.
The E/T ratio was associated with AIS in both crude
and multivariable analyses. After adjustment for other
confounding factors, multivariate logistic regression ana-
lyses found that participants with the highest E/T ratio
were more likely to have AIS (OR: 3.084; 95 % CI:
1.616–5.886; P < 0.001) compared with those in the first
tertile (Table 3). The adjusted OR of the highest E/T
ratio was more obvious than that of SBP (OR: 1.016;
95 % CI: 1.003–1.029; P = 0.013) and HTN (OR: 1.750;
95 % CI: 1.026–2.984; P = 0.040).
Subsequently, logistic regression analyses were con-
ducted to evaluate the risk factors related to early un-
favorable outcomes (Table 4). In univariate logistic
regression analyses, the E/T ratio had a statistically sig-
nificant association with early unfavorable functional
outcomes (P = 0.001). With adjustments for confounding
factors, significant variables for unfavorable outcomes
were age, HTN, atrial fibrillation, “on admission” NIHSS
score, stroke subtype, and estradiol level. After adjusting
for all other significant outcome predictors, the E/T ra-
tio remained an independent unfavorable outcome pre-
dictor with an adjusted OR of 1.167 (95 % CI: 1.053–
1.294; P = 0.003). The other significant variables for early
unfavorable functional outcomes were old age (OR:
1.061; 95 % CI: 1.006–1.119; P = 0.029), and “on admis-
sion” NIHSS score (OR: 1.539; 95 % CI: 1.267–1.871; P <
0.001) (Table 4).
The E/T ratio of the patients with early unfavorable
functional outcomes was significantly higher compared
to those with favorable outcomes (P < 0.001) (Fig. 1).
Discussion
Our study demonstrated that the E/T ratio was inde-
pendently associated with both AIS and poor early func-
tional outcomes. In this study, the highest tertile of the
E/T ratio was significantly associated with AIS. Our
findings suggest that the E/T ratio may be a possible in-
dependent biological marker of AIS. Furthermore, an el-
evated E/T ratio may be used to predict early
unfavorable functional outcomes. To the best of our
knowledge, the current study is the first to investigate
the inter-relationship between the ratio of sex hormones
and early functional neurological outcomes in patients
with AIS.
The presence of sexual dimorphism and their function
has now been supported by evidence from the various
fields of genetics, epigenetics, immunology, cellular
physiology, and neurosciences. These mechanisms in-
clude apoptotic signaling cascades in neurons and glia,
resident microglial activation, neuroglial response to
ionic imbalance, autophagy, and mitochondrial toxicity
[14]. In addition, the different effects of sexual hormone
levels on the disease in males and females should be
considered.
Clinical trials have demonstrated that estrogen in-
crease the stroke incidence and severity in elderly
women [2]. There is also evidence that estrogen therapy
may increase thrombotic conditions and the risk of
stroke. This suggests that hormones affect not only the
brain, but also the coagulation system [15]. Similar
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trends were also observed in experimental stroke
models. When administered to aged female rodents, es-
trogen paradoxically increased infarct volume after is-
chemic stroke [16]. These neurotoxic effects may be
associated with a decrease in the utilization of insulin-
like growth factor 1, a neuroprotective agent that de-
creases with age and is downregulated by estrogen treat-
ment [17]. However, these studies were conducted only
in women. Furthermore, the effects of estrogen therapy
duration or dose on the experimental results were un-
clear [18].
Estradiol is the most potent endogenous estrogen. Es-
tradiol is the main female sex hormone and plays an im-
portant role in the promotion of secondary sexual
characteristics, and development of the reproductive sys-
tem and breast tissue [10, 19]. Estradiol affects the brain
through estrogen receptors (ER), most of which act
through ERα of endothelium and smooth muscle cell,
increase the transcription of pro-survival gene, and de-
crease pro-apoptotic gene [20–22]. Estradiol increases
activation of extracellular signal-regulated kinase, which
is involved in overall cell survival, inhibits the pro-
apoptotic c-Jun N-terminal kinase pathway, and in-
creases endothelial nitric oxide synthase and prostacyclin
synthase, leading to vasodilation [20–23]. It is also
known that estradiol may increase endothelial progenitor
cell proliferation, which promotes angiogenesis [20].
Considering these mechanisms, estradiol is thought to
have a neuroprotective effect basically, but some clinical
studies have drawn different results from hypothesis.
One study obtained blood samples from 302 post-
menopausal women hospitalized with AIS and found an
Table 1 Distribution of demographic and clinical characteristics among acute ischemic stroke patients and controls
AIS (n=146) Control (n=152) P-value
Age, years 70.62 ± 10.67 70.51 ± 10.49 0.929
Systolic blood pressure, mmHg 147.12 ± 24.20 134.16 ± 22.60 <0.001
Diastolic blood pressure, mmHg 83.40 ± 19.18 75.32 ± 14.10 <0.001
Height, m 1.67 ± 0.07 1.64 ± 0.09 0.001
Weight, kg 65.80 ± 8.98 64.21 ± 10.72 0.167
Body mass index, kg/m2 23.55 ± 2.88 23.84 ± 3.27 0.413
Hypertension 77 (52.7) 58 (38.2) 0.014
Diabetes mellitus 39 (26.7) 28 (18.4) 0.097
Smoking, current 46 (31.5) 34 (22.4) 0.089
Alcohol, current 57 (39.0) 51 (33.6) 0.337
Cardiovascular diseasea 32 (21.9) 19 (12.5) 0.033
Hyperlipidemia 61 (41.8) 49 (32.2) 0.094
Atrial fibrillation 26 (17.8) 14 (9.2) 0.040
CKD 33 (22.6) 17 (11.2) 0.013
Total cholesterol, mmol/L 5.24 ± 1.10 4.93 ± 1.06 0.014
Triglyceride, mmol/L 1.86 ± 0.99 1.60 ± 1.04 0.032
HDL-cholesterol, mmol/L 1.17 ± 0.26 1.23 ± 0.33 0.083
LDL-cholesterol, mmol/L 3.35 ± 1.04 3.15 ± 0.86 0.072
HbA1c, % 6.13 ± 1.64 5.83 ± 1.17 0.074
eGFR, mL/min/1.73 m2 69.93 ± 15.39 74.69 ± 13.64 0.005
Estradiol, pmol/L 71.63 ± 50.45 62.33 ± 49.70 0.110
Total testosterone, nmol/L 13.62 ± 7.66 15.53 ± 10.18 0.070
Free testosterone, nmol/L 0.25 ± 0.12 0.25 ± 0.09 0.827
Progesterone, nmol/L 1.71 ± 0.70 1.84 ± 0.63 0.098
17-OH progesterone, nmol/L 4.91 ± 1.84 4.96 ± 2.09 0.809
E/T ratio 6.75 ± 5.97 4.72 ± 4.38 0.001
E/free T ratio 366.43 ± 342.95 291.50 ± 332.19 0.056
Data are expressed as the mean ± SD, number (%)
AIS acute ischemic stroke, CKD chronic kidney disease, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate, E/T
ratio estradiol-to-testosterone ratio, E/free T ratio estradiol-to-free testosterone ratio
aCardiovascular disease includes coronary heart disease, heart failure, or peripheral arterial disease
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association between higher estradiol levels and stroke se-
verity, 1-month mortality, and poor functional outcomes
[24]. The study reported that estradiol levels remained
independently associated with the aforementioned pa-
rameters, even after correction of confounders. The
study concluded that stroke itself may elevate estradiol
levels as an endogenous protective mechanism. Another
study reported that higher circulating estradiol levels in
late post-menopausal women were associated with
higher mortality, independent of age and multiple con-
founders [25]. This study also suggested that the pro-
thrombotic effects of estradiol may explain the high rate
of thrombotic events observed in post-menopausal
women. Lee et al. suggested that post-menopausal
women with high endogenous free estradiol levels had
2.3-fold greater odds of stroke, independent of age [26].
However, these prospective studies can only reveal asso-
ciations, not causality [24–26]. Nevertheless, higher
levels of estradiol may be a marker of cerebrovascular
disease and could help in identification of patients with
AIS who are at risk of worsening unfavorable functional
outcomes and mortality [24, 25].
Related studies of testosterone levels provide conflict-
ing data on the true effects of the hormone on visceral
adiposity, independent of other sex hormones. High
serum testosterone is associated with reduced subcuta-
neous and increased abdominal adiposity in women,
while low testosterone is associated with the same effect
in men [27–29]. In older men, sex hormone levels do
not decrease as rapidly as in menopausal women how-
ever, testosterone levels decline steadily with age
[30].These declining testosterone levels have been re-
ported to be associated with elevated visceral adiposity
in older men [31]. This may play a role in increased risk
of cardiovascular diseases in aging men. Low testoster-
one levels are associated with increased systemic
Table 2 Participant characteristics according to the estradiol-to-testosterone ratio tertile
Tertiles of estradiol-to-testosterone ratio P-
value1st (<2.33) 2nd (2.37-6.39) 3rd (6.53<)
n = 99 n = 100 n = 99
Age, years 69.42 ± 11.05 68.15 ± 10.73 74.13 ± 8.91 <0.001
Prevalence of AIS 33 (33.3) 50 (50.0) 63 (63.6) <0.001
Systolic blood pressure, mmHg 134.84 ± 23.38 142.56 ± 25.18 144.11 ± 23.33 0.015
Diastolic blood pressure, mmHg 76.24 ± 15.67 80.70 ± 18.85 80.88 ± 16.79 0.100
Body mass index, kg/m2 24.13 ± 3.12 23.00 ± 3.22 23.97 ± 2.80 0.019
Hypertension 49 (49.5) 44 (44.0) 42 (42.4) 0.586
Diabetes mellitus 13 (13.1) 32 (32.0) 22 (22.2) 0.006
Smoking, current 25 (25.3) 19 (19.0) 36 (36.4) 0.020
Alcohol, current 32 (32.3) 30 (30.0) 46 (46.5) 0.032
Cardiovascular diseasea 13 (13.1) 24 (24.0) 14 (14.1) 0.090
Hyperlipidemia 33 (33.3) 41 (41.0) 36 (36.4) 0.553
Atrial fibrillation 15 (15.2) 8 (8.0) 17 (17.2) 0.143
CKD 14 (14.1) 21 (21.0) 15 (15.2) 0.388
Total cholesterol, mmol/L 4.94 ± 1.14 5.02 ± 1.07 5.29 ± 1.03 0.060
Triglyceride, mmol/L 1.70 ± 1.02 1.63 ± 0.95 1.85 ± 1.08 0.307
HDL-cholesterol, mmol/L 1.21 ± 0.30 1.15 ± 0.31 1.24 ± 0.29 0.107
LDL-cholesterol, mmol/L 3.12 ± 0.96 3.26 ± 0.92 3.36 ± 0.98 0.202
HbA1c, % 5.72 ± 1.00 6.11 ± 1.77 6.10 ± 1.38 0.089
eGFR, mL/min/1.73 m2 74.64 ± 14.27 70.44 ± 14.16 72.02 ± 15.45 0.125
E2 (estradiol), pmol/L 26.69 ± 19.96 61.70 ± 36.44 112.32 ± 46.40 <0.001
Total testosterone, nmol/L 16.57 ± 10.87 16.09 ± 8.93 11.11 ± 5.68 <0.001
Free testosterone, nmol/L 0.24 ± 0.08 0.26 ± 0.10 0.24 ± 0.14 0.498
Progesterone, nmol/L 1.61 ± 0.54 1.91 ± 0.74 1.81 ± 0.66 0.004
17-OH progesterone, nmol/L 4.60 ± 1.81 5.33 ± 1.98 4.87 ± 2.05 0.030
Data are expressed as the mean ± SD, number (%)
AIS acute ischemic stroke, CKD chronic kidney disease, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate
aCardiovascular disease includes coronary heart disease, heart failure, or peripheral arterial disease
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inflammation [32] and endothelial dysfunction [33], both
of which contribute to atherosclerosis. Epidemiological
studies have shown that low testosterone levels inde-
pendently predict the atherosclerosis development [34,
35]. Some meta-analyses have demonstrated that low
testosterone levels increase the risk of major cardiovas-
cular diseases as well as mortality [36, 37]. While many
studies have reported the association between mortality
in men and low circulating levels of testosterone [38],
few have investigated the association between testoster-
one and the incidence of AIS. Levels of testosterone
fluctuate throughout life in males. Increased levels ob-
served in young men and decreased levels of the hor-
mone in older men have been shown to increase the risk
of ischemic stroke [39, 40]. It has also been hypothesized
that aged men have reduced functional outcomes after
AIS as a result of the progressive decreased testosterone,
in contrast to the neuroprotective effect observed in
the female brain [41]. Although the effects of estra-
diol and testosterone vary greatly depending on age
and sex, it is reported that in elderly men, as total
testosterone levels decrease, the incidence of stroke
increases and functional outcomes may be poor even
after adjusting for existing cardiovascular risk factors
[42–44]. This is probably due to the anti-
inflammatory and anti-oxidant effects of testosterone
itself on brain endothelial cells and vascular smooth
muscle cells in the pathologic state, but suggests that
the balance between estradiol and testosterone may
also be important [45, 46]. Based on these results, in
order to determine the impact of testosterone on the
outcomes of ischemic stroke, a more robust study
should be designed that considers the levels of en-
dogenous testosterone and other sex hormones.
Table 3 Univariate and multivariate analyses of risk factors for acute cerebral infarction
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Systolic blood pressure 1.024 1.014-1.035 <0.001 1.016 1.003-1.029 0.013
Diastolic blood pressure 1.031 1.015-1.046 <0.001 1.015 0.998-1.033 0.085
Body mass index 0.969 0.900-1.044 0.412
Hypertension 1.809 1.140-2.868 0.012 1.750 1.026-2.984 0.040
Diabetes mellitus 1.614 0.931-2.798 0.088
Smoking, current 1.596 0.952-2.678 0.076
Alcohol, current 1.268 0.790-2.036 0.325
Cardiovascular diseasea 1.965 1.057-3.654 0.033 1.374 0.660-2.863 0.396
Hyperlipidemia 1.509 0.940-2.421 0.089
Atrial fibrillation 2.136 1.067-4.276 0.032 1.998 0.923-4.326 0.079
CKD 2.319 1.227-4.382 0.010 1.709 0.648-4.511 0.279
Total cholesterol 1.305 1.053-1.618 0.015 1.144 0.883-1.480 0.308
Triglyceride 1.288 1.018-1.631 0.035 1.313 0.997-1.728 0.053
HDL-cholesterol 0.510 0.237-1.098 0.085
LDL-cholesterol 1.248 0.980-1.589 0.072
HbA1c 1.164 0.984-1.377 0.077
eGFR 0.977 0.962-0.993 0.006 0.989 0.965-1.014 0.397
E2 (estradiol) 1.004 0.999-1.008 0.110
Total testosterone 0.976 0.950-1.002 0.075
Free testosterone 0.791 0.099-6.339 0.825
Progesterone 0.746 0.526-1.057 0.099
17-OH progesterone 0.986 0.878-1.107 0.808
E/T ratio
1st tertile Reference Reference
2nd tertile 2.000 1.128-3.547 0.018 1.813 0.955-3.442 0.069
3rd tertile 3.500 1.950-6.283 <0.001 3.084 1.616-5.886 0.001
OR odds ratio, CI confidence interval, CKD chronic kidney disease, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration
rate, E/T ratio estradiol-to-testosterone ratio
aCardiovascular disease includes coronary heart disease, heart failure, or peripheral arterial disease
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We have suggested a unique concept in this study,
namely the E/T ratio, and investigated the association
between this ratio, AIS, and unfavorable functional out-
comes. The novelty of this work is that it presents a new
form of biomarker by combining estradiol and testoster-
one to quantitatively identify the influence of acute is-
chemic stroke. In this study, the E/T values showed
clear differences between the two groups, but the values
of estradiol and testosterone did not show statistical dif-
ferences. This is probably considered a problem of diag-
nostic values. Although not statistically significant, there
were an increase in estradiol and a decrease in
testosterone level in AIS group, compared with control.
The estradiol and testosterone levels were affected by
age and sex. This study is also meaningful in comparing
estradiol and testosterone respectively in patients with
AIS, but more focused suggests that using the E/T ratio
can increase the diagnostic value. This study suggests
that estradiol and testosterone may have clinical signifi-
cance in AIS patients, but lower testosterone level com-
pared to estradiol level is more correlated with AIS and
early unfavorable functional outcome. E/T ratio was
concluded to be a useful biomarker for AIS and early
unfavorable functional outcomes. The results of our
Table 4 Univariate and multivariate analyses for early unfavorable outcomes
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age 1.087 1.047-1.128 <0.001 1.061 1.006-1.119 0.029
Systolic blood pressure 0.994 0.981-1.008 0.405
Diastolic blood pressure 1.001 0.984-1.018 0.886
Body mass index 1.018 0.909-1.141 0.752
Hypertension 1.985 1.024-3.848 0.042 2.601 0.849-7.963 0.094
Diabetes mellitus 1.981 0.941-4.170 0.072
Smoking, current 1.076 0.535-2.166 0.837
Alcohol, current 1.328 0.681-2.587 0.405
Cardiovascular diseasea 1.646 0.747-3.627 0.217
Hyperlipidemia 1.889 0.970-3.677 0.061
Atrial fibrillation 2.556 1.054-6.194 0.038 1.657 0.435-6.319 0.460
CKD 1.773 0.809-3.883 0.153
Total cholesterol 1.001 0.994-1.009 0.750
Triglyceride 0.998 0.994-1.001 0.221
HDL-cholesterol 0.975 0.944-1.008 0.134
LDL-cholesterol 1.003 0.995-1.011 0.481
HbA1c 1.034 0.848-1.261 0.742
eGFR 0.984 0.963-1.006 0.148
Admission NIHSS score 1.682 1.395-2.029 <0.001 1.539 1.267-1.871 <0.001
Stroke subtypes
Large artery atherosclerosis Reference
Cardioembolism 2.177 0.905-5.233 0.082 2.112 0.571-7.813 0.263
Small vessel disease 0.260 0.087-0.773 0.015 0.206 0.034-1.237 0.084
Unknown/undetermined causes 0.390 0.145-1.047 0.062 0.590 0.143-2.427 0.464
E2 (estradiol) 1.011 1.004-1.018 0.002 1.003 0.993-1.014 0.507
Total testosterone 0.961 0.919-1.005 0.080
Free testosterone 0.169 0.012-2.450 0.192
Progesterone 1.616 0.988-2.642 0.056
17-OH progesterone 0.979 0.820-1.170 0.815
E/T ratio 1.134 1.052-1.221 0.001 1.167 1.053-1.294 0.003
OR odds ratio, CI confidence interval, CKD chronic kidney disease, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration
rate, NIHSS National Institutes of Health Stroke Scale, E/T ratio estradiol-to-testosterone ratio
aCardiovascular disease includes coronary heart disease, heart failure, or peripheral arterial disease
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study are consistent with some previously reported ob-
servations. In a study on middle-aged men, wherein tes-
tosterone or estradiol was measured by immunoassay,
higher estradiol levels were associated with cardiovascu-
lar disease [47]. In a study on elderly men, higher total
testosterone using mass spectrometry was associated
with a lower incidence of cardiovascular events, with
similar hazard ratio in men with and without pre-
existing cardiovascular disease [48]. Another study in
aged men using mass spectrometry for hormonal ana-
lysis found no association between testosterone and car-
diovascular events, defined as myocardial infarction
(MI), stroke, or cardiovascular disease-related death [49].
A recent study on elderly men reported that higher
plasma testosterone is an associated biomarker for re-
duced risk of stroke, but not MI [44]. Another recent
study reported that extremely low plasma testosterone
levels were associated with a high risk of ischemic stroke
in men, and that this was caused by being overweight,
and HTN [50]. Testosterone was found to independently
induce endothelial relaxation through secretion of endo-
thelial nitric oxide synthase, which causes vasodilation
[51]. In obese men, the reduction in these neuroprotec-
tive effects may be related to development of AIS, due to
increase in blood pressure. Furthermore, the conversion
of testosterone to estradiol arises in adipose tissue by
aromatization, and excessive adipose tissue may reduce
plasma testosterone concentrations [50, 52]. Therefore,
the applicability of the E/T ratio, and the association be-
tween higher E/T ratio and prevalence of AIS should be
considered.
Several limitations should be considered for the
present study. First, this was a single-center study con-
ducted on a single race. The sample size was small for
the results may not be generalizable to other demo-
graphic groups. A large-scale, multi-center external val-
idation of the current study is necessary. Second, we
primarily considered cross-sectional observational data,
which may reduce accuracy. Particularly, female were
excluded from this study because plasma sex hormones
vary widely depending on menstruation or menopause.
Such variations are also observed in men. However, not
to the extent seen in women. It would be interesting to
conduct a study that distinguishes the causal relationship
between sex hormones and stroke in pre- and post-
menopausal women. Furthermore, it would be also in-
teresting to conduct a large-scale study comparing re-
productive and elderly age for various sex hormones in
stroke. Third, we did not serially measure plasma sex
hormone levels, which prevented us from determining
the cause and effect relationship between the hormones
and AIS or other functional outcomes. We did not illus-
trate the longitudinal relationship between sex hormones
and AIS. Fourth, the E/T ratio may be related to inflam-
mation and short-term outcomes, which may be related
to the infarct volume, but could not be measured in this
Fig. 1 Boxplot of the estradiol/testosterone (E/T) ratio according to early functional neurological outcomes
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study. MRI volumetry should be used to provide more
accurate and reliable information on infarct volume. A
large-scale study using this technique is warranted. Fifth,
access to the proven gold standard mass spectrometry
estradiol measurement technique for routine clinical use
is limited. Therefore, immunoassay, as used in this study,
may have resulted in inaccurate measurement of low
serum concentrations of estradiol in men, which could
lead to overestimation of estradiol [53]. Sixth, there was
no difference in BMI between stroke and control group
in this study. In univariate analysis, BMI did not show
any association with AIS or early outcome, and correl-
ation analysis also showed no correlation with estradiol
or testosterone. However, in several previous studies,
BMI is known to be closely related to hormone level and
particularly to estradiol level in postmenopausal women.
BMI has been reported to be positively correlated with
estrone concentrations in older estradiol therapy users
[54], and there are studies showing that serum estrogen
in post-menopausal women is directly associated with
BMI [55, 56]. It is also known that elevated BMI alters
the hypothalamus-pituitary-gonadal axis, hormone
levels, and gametogenesis [57]. Therefore, a large scale
studies including post-menopausal women are needed,
considering the relationship between BMI and sex hor-
mones. Finally, since early functional outcomes were
assessed in this study, it is necessary to verify the associ-
ation with long-term neurological outcomes. Despite
these limitations, the results suggest that the E/T ratio
may be of diagnostic and prognostic value for AIS.
Conclusions
Our study demonstrated a relationship between the E/T
ratio and AIS. The E/T ratio may be a useful, non-
invasive, convenient indicator that potentially predicts
early unfavorable functional outcomes in male patients
with AIS. Further large-scale investigations are necessary
to explore the causal associations among sex hormones,
E/T ratio, AIS, and functional neurological outcomes.
Estrogen and progesterone are neuroprotective and anti-
inflammatory hormones in various disease models of the
brain, particularly in acute inflammatory conditions such
as stroke. Several recent studies have revealed conflicting
data and indicate that androgens can either protect
against or exacerbate ischemic damage. However, it re-
mains to be determined whether sex hormones affect
the acute stage of ischemic stroke. Thus, large scale add-
itional studies are warranted to explore the potential
mechanisms underlying this association and to separ-
ately evaluate reproductive age and elderly, including fe-
male patients.
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